Atenolol vs Other Beta-Blockers in Hypertension
Author Information
Author(s): Aursnes Ivar, Osnes Jan-Bjørn, Tvete Ingunn Fride, Gåsemyr Jørund, Natvig Bent
Primary Institution: University of Oslo
Hypothesis
Does atenolol differ from other β-adrenergic blockers in terms of effectiveness for hypertensive patients?
Conclusion
Atenolol is not representative of the β-adrenergic blocker class and is less effective than non-atenolol β-blockers in treating hypertension.
Supporting Evidence
- Atenolol has been shown to have higher death rates compared to other β-blockers.
- Patients on non-atenolol β-blockers had a 13% lower risk of myocardial infarction.
- The credibility interval for the risk ratio indicates statistical significance.
- Atenolol does not improve long-term prognosis after myocardial infarction.
Takeaway
Atenolol is not as good as other similar medications for treating high blood pressure, so doctors should use the other medications instead.
Methodology
Bayesian statistical analysis of published data from multiple studies.
Potential Biases
Potential biases from the original studies included in the meta-analysis.
Limitations
The analysis relied on previously published data, which may have inherent biases.
Participant Demographics
Hypertensive patients treated with various β-adrenergic blockers.
Statistical Information
Confidence Interval
0.75 to 0.99
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website